Novosom Licenses Next-Generation CD40 Targets From Isis
This article was originally published in The Pink Sheet Daily
Executive Summary
Novosom plans to use Isis’ antisense oligonucleotides targeting CD40 with its proprietary Smarticles technology to enhance delivery.